Data Insights

Crizotinib by Pfizer for Refractory Multiple Myeloma: Likelihood of Approval

Crizotinib is under clinical development by Pfizer and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Crizotinib in Refractory Multiple Myeloma

Data Insights

Crizotinib by Pfizer for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Crizotinib is under clinical development by Pfizer and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Crizotinib in Triple-Negative Breast Cancer (TNBC)

Data Insights

Crizotinib by Pfizer for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Crizotinib is under clinical development by Pfizer and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative...

Likelihood of Approval and Phase Transition Success Rate Model - Crizotinib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Crizotinib by Pfizer for Uveal Melanoma: Likelihood of Approval

Crizotinib is under clinical development by Pfizer and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Crizotinib in Uveal Melanoma

Data Insights

Crizotinib by Pfizer for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

Crizotinib is under clinical development by Pfizer and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According to...

Data Insights

Crizotinib by Pfizer for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Crizotinib is under clinical development by Pfizer and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...

Data Insights

Crizotinib by Pfizer for Metastatic Uveal Melanoma: Likelihood of Approval

Crizotinib is under clinical development by Pfizer and currently in Phase III for Metastatic Uveal Melanoma. According to GlobalData, Phase...

Data Insights

Crizotinib by Pfizer for Glioblastoma Multiforme (GBM): Likelihood of Approval

Crizotinib is under clinical development by Pfizer and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...

Data Insights

Crizotinib by Pfizer for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Crizotinib is under clinical development by Pfizer and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Data Insights

Crizotinib by Pfizer for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Crizotinib is under clinical development by Pfizer and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative...